Market Cap | 44.15M | P/E | - | EPS this Y | 2.10% | Ern Qtrly Grth | - |
Income | -27.21M | Forward P/E | -1.92 | EPS next Y | 53.90% | 50D Avg Chg | -2.00% |
Sales | 4.09M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 6.00% |
Dividend | N/A | Price/Book | 1.74 | EPS next 5Y | - | 52W High Chg | -42.00% |
Recommedations | 2.30 | Quick Ratio | 0.26 | Shares Outstanding | 9.23M | 52W Low Chg | 131.00% |
Insider Own | 19.03% | ROA | -41.84% | Shares Float | 3.36M | Beta | 0.79 |
Inst Own | 38.87% | ROE | -118.62% | Shares Shorted/Prior | 20.89K/39.05K | Price | 0.84 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 240,174 | Target Price | 20.00 |
Oper. Margin | -420.00% | Earnings Date | Mar 29 | Volume | 14,557 | Change | 2.54% |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
HC Wainwright & Co. | Buy | Jan 8, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Sullivan Eddie Joe | Chief Executive Offi.. Chief Executive Officer | Dec 07 | Buy | 0.88 | 1,740 | 1,531 | 5,232,304 | 12/08/23 |
King Michael | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 30 | Buy | 0.900 | 5,000 | 4,500 | 5,000 | 11/30/23 |
HAMILTON CHRISTINE E | Director Director | Sep 13 | Buy | 0.7297 | 10,000 | 7,297 | 4,993,090 | 09/14/22 |
Sullivan Eddie Joe | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Sep 07 | Buy | 0.7368 | 14,000 | 10,315 | 5,230,564 | 09/08/22 |